Praxis Precision (PRAX) completed the planned discussion with the FDA leading to the confirmation to file a New Drug Application for relutrigine in SCN2A and SCN8A developmental and epileptic ...
Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback